Therapeutic, nasally delivered DNA vaccine fuses two genes to help fight tuberculosis

Therapeutic, nasally delivered DNA vaccine fuses two genes to help fight tuberculosis

In a paper published in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB) that fuses two genes with the goal of directing the immune system to fight drug-tolerant bacterial "persisters" that can survive prolonged antibiotic therapy and contribute to disease relap…

Johns Hopkins Team Develops Therapeutic, Nasally Delivered DNA Vaccine for Tuberculosis

In a paper published today in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB).

JCI Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models

Mycobacterium tuberculosis remains a global health crisis, ranking among the deadliest infectious diseases worldwide. In response to the WHO’s call for therapeutic vaccines to complement antibiotic regimens and reduce tuberculosis (TB) treatment duration, we developed an intranasal DNA vaccine fusing the M. tuberculosis stringent response gene relMtb with the gene encoding the DC-targeting chemokine Mip3a (also known as CCL20). Administered alon…

Johns Hopkins Team Develops Nasal DNA Vaccine as New Therapeutic Approach

In a groundbreaking advancement in the fight against one of humanity’s oldest and deadliest foes, researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have unveiled a novel therapeutic DNA vaccine designed to combat tuberculosis (TB). Detailed in a recent publication in the Journal of Clinical Investigation, this innovative vaccine […]